1. Home
  2. ANY vs INDP Comparison

ANY vs INDP Comparison

Compare ANY & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sphere 3D Corp.

ANY

Sphere 3D Corp.

HOLD

Current Price

$1.91

Market Cap

8.1M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$1.65

Market Cap

5.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANY
INDP
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
5.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ANY
INDP
Price
$1.91
$1.65
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
210.0K
45.6K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,181,000.00
N/A
Revenue This Year
$15.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.27
52 Week High
$2.48
$13.24

Technical Indicators

Market Signals
Indicator
ANY
INDP
Relative Strength Index (RSI) 52.74 49.75
Support Level $1.24 $1.64
Resistance Level $2.48 $2.08
Average True Range (ATR) 0.23 0.21
MACD -0.02 0.01
Stochastic Oscillator 31.24 80.37

Price Performance

Historical Comparison
ANY
INDP

About ANY Sphere 3D Corp.

Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: